<DOC>
	<DOCNO>NCT02972463</DOCNO>
	<brief_summary>The purpose study determine optimal dose IgY assess change inflammatory marker , C-reactive protein investigate effect IgY gut microbiome assess 16 RNA sequence fecal sample .</brief_summary>
	<brief_title>The Influence IgY Max Inflammatory Markers Gut Microbiome</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male female adult age 18 60 ( inclusive ) Selfreported complaint minor gastrointestinal symptom ( i.e . occasional gas , bloating , etc . ) Nonsmoker , exsmoker ≥6 month Body mass index 25.0 34.9kg/m2 ( inclusive ) Female subject childbearing potential [ i.e . surgically sterilize postmenopausal ( great one year since last menses ) ] must negative urine pregnancy test must use effective birth control method Willing avoid alcohol consumption 24 h prior every clinic visit Willing maintain regimen medication supplement know alter GI function ( include , limited , iron supplement , calcium , antidepressant ) Willing maintain stable body weight , activity level dietary pattern except use study product , direct Willing able provide inform write consent Pregnancy lactation , subject unwilling take appropriate contraceptive duration study Use prescription nonsteroidal antiinflammatory drug ( daily use counter nonsteroidal antiinflammatory drug &gt; 1month ) , steroid , corticosteroid , prescription antiinflammatory drug within 3 month prior visit 1 Unstable use ( i.e . initiation change dose ) antihypertensive medication thyroid hormone replacement medication within 3 month prior visit 1 Use weightloss program weightloss medication ( prescription overthe counter ) include , limited , lipase inhibitor , within 3 month prior visit Use counter prescription laxatives stool softener within 1 month prior baseline ( V2 ) Use antibiotic ( topical ) within 2 month prior baseline ( V2 ) Use prebiotic supplement ( e.g . fructans galactooligosaccharides ( FOS , GOS ) , psyllium , fiber , inulin ) probiotic supplement ( i.e . live microorganism ) within 4 week baseline ( V2 ) consumption food fortify prebiotics ( e.g . inulin ) probiotic within 2 week baseline ( V2 ) History blood clot disorder use coagulationinhibiting drug ( e.g . warfarin ) Individuals achlorhydria Presence major disease diabetes , gastrointestinal disease , cardiovascular disease , pancreatic , renal , liver disease Chronic diarrhea constipation , irritable bowel syndrome , inflammatory bowel disease Abdominal gastrointestinal surgery within previous 12 month plan abdominal gastrointestinal surgery next 4 month Recent gastrointestinal foodborne illness ( within 1 month prior visit 1 ) History neurological disease ( e.g . Parkinson 's disease , stroke , traumatic brain injury , etc . ) History cancer ( exclude nonmelanoma skin cancer basal cell carcinoma ) past 5 year Uncontrolled hypertension define seat rest systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg Abnormal laboratory test result clinical significance , include , limited ALT AST ≥1.5X upper limit normal screening ( visit 1 ) Presence history ( past 6 month ) alcohol drug abuse ; alcohol use &gt; 2 standard alcoholic drink per day Extreme dietary habit ( e.g . vegan low carbohydrate diet ) Subject know allergy intolerance test product placebo Subject unwilling unable abide requirement protocol Any condition would interfere subject 's ability comply study instruction , might confound interpretation study , put subject risk Subject take investigational health product participate research study within 30 day prior first study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastrointestinal</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Inflammation</keyword>
</DOC>